# The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AA

> **NCT05518331** · NA · UNKNOWN · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 39 (estimated)

## Conditions studied

- Refractory Aplastic Anemia

## Interventions

- **DRUG:** avatrombopag

## Key facts

- **NCT ID:** NCT05518331
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2026-01-01
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2022-08-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05518331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05518331, "The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AA". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05518331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*